L694247 (TFA) is a selective 5-HT1D agonist with pIC50 values of 10.03, 8.64, 6.42, and 5.66 for 5-HT1D, 5-HT1A, 5-HT1C, and 5-HT1E receptors, respectively.

ZH8659 hydrochloride is a trace amine-associated receptor 1 (TAAR1)-Gq agonist. ZH8659 hydrochloride can be used for the research of neurological disorders.

(1-(7-Bromoheptyl)piperidin-4-yl)methanamine is a PROTAC linker. (1-(7-Bromoheptyl)piperidin-4-yl)methanamine can be used in synthesis ZS3-046.

E3 Ligase Ligand-linker Conjugate 210 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 210 can be used to synthesize PROTAC CB1R Degrader-1.

2-[4-(Aminomethyl)triazol-1-yl]ethanamine is a PROTAC Linker. 2-[4-(Aminomethyl)triazol-1-yl]ethanamine can be used to synthesize PROTAC CB1R Degrader-1.

Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM. Refinicopan inhibits rabbit erythrocyte hemolysis with an IC50 of 41 nM. Refinicopan exhibits excellent pharmacokinetic and pharmacodynamic activity.

JNJ-27390467 is a potent, orally active, and selective tryptase inhibitor (human β-tryptase IC50 = 3.6 nM, Ki = 3.7 nM). JNJ-27390467 exhibits excellent selectivity over trypsin of ~5000-fold. JNJ-27390467 shows effects in animal models of airway inflammation. JNJ-27390467 can be used for allergic asthma research.

YL6113 is a potent and selective dual inhibitor of metallo-β-lactamases (MBLs) and serine-β-lactamases (SBLs). YL6113 shows inhibitory effect to MBLs, such as NDm-1, VIM-2, IMP-1, with IC50 values of 0.25, 27.16 and 3.55 μM. YL6113 shows inhibitory effect to SBLs, such as KPC-2, AmpC, OXA-48, with IC50 values of 0.2, 34.1 and 1.31 μM. YL6113 enhances the antibacterial efficacy of Meropenem against carbapenem-resistant Gram-negative bacteria. YL6113 can be used for the research of infection.

7-MAD-MDCPT TFA, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs).

7-MAD-MDCPT hydrochloride, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs).

ER ligand-11 is the ligand for ERα and can be used for synthesis of PROTACs, such as PROTAC ERα Degrader-12.

CEB-1604 is an NMDA receptor antagonist. CEB-1604 inhibits NMDA-induced currents in oocytes transfected with NMDA receptor isoforms (NR1/NR2A, NR1/NR2B, NR1/NR2C, NR1/NR2D) with IC50 values ranging from 5 to 12 μM. CEB-1604 abolishes NMDA-dependent epileptiform discharges in rat cortical wedge preparations and reduces the depolarizing effects of NMDA. CEB-1604 can be used in the research field of neurological damage diseases.

Gly-7-MAD-MDCPT (Compound 4b) TFA is an anticancer agent. Gly-7-MAD-MDCPT TFA is a Camptothecin compound, which shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM.

Gly-7-MAD-MDCPT (Compound 4b) hydrochloride is an anticancer agent. Gly-7-MAD-MDCPT hydrochloride is a Camptothecin compound, which shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM.

Gly-Gly-Gly-PEG3-TCO TFA is a 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

BTR2000-Gly-Gly-Gly TFA is a E3 ligase ligand-linker conjugate (KLHL20) that can be used for the synthesis of PROTAC BTR2004.

(R,S,S)-VH032-Me-glycine is an E3 ligase ligand-linker conjugate. (R,S,S)-VH032-Me-glycine can be used to synthesize XF067-68.

M2 ion channel blocker-2 (Compound 10) is a M2 channel blocker. M2 ion channel blocker-2 significantly blocks wild-type and mutant M2 (L27F and V27A) ion channels. M2 ion channel blocker-2 has potent antiviral activity against HCoV-229E (EC50: 4.7  μM in cytopathic effect) but not against influenza A virus. M2 ion channel blocker-2 has no significant inhibition of hERG and cytochrome P450 (CYP1A2, CYP2C19, and CYP3A4) activity.

SMU-L11-R is a selective TLR7 agonist with an EC50 of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits  MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8+T cells. SMU-L11-R shows potential in colorectal cancer studies.

ddATP (lithium) (2',3'-Dideoxyadenosine 5'-triphosphate (lithium)) is an active metabolite of 2',3'-dideoxyinosine and a DNA polymerase chain elongation inhibitor. ddATP (lithium) is used in Sanger DNA sequencing and in research related to viral infection[1][2][3][4][5].

2-5A (5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine) pentasodium is a 5'-triphosphorylated (2',5') oligoadenylate. 2-5A pentasodium is an immunotransmitter that fuels RNase L immunity. 2-5A pentasodium degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its endoribonuclease activity. 2-5A pentasodium can be used in RSV and cancer research.

2-5A is a 5'-triphosphorylated (2',5') oligoadenylate. 2-5A is an immunotransmitter that fuels RNase L immunity. 2-5A degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its endoribonuclease activity. 2-5A can be used in RSV and cancer research.

Adenosyl-(3′→5′)-uridine (ApU) sodium is a nucleotide, which is composed of an adenine base and a uracil sugar molecule through a 3'-5' phosphodiester bond. Adenosyl-(3′→5′)-uridine (ApU) sodium participates in the biological processes, such as gene expression regulation, signal transduction, and protein synthesis.

NAADP tetrasodium is a second messenger. NAADP tetrasodium releases Ca2+ from acidic endosomes and lysosomes. NAADP tetrasodium can be used to study cancer (such as oral squamous cell carcinoma, malignant melanoma) and angiogenesis-related diseases.

Parent CDN is a cyclic dinucleotide and a STING agonist. Parent CDN exhibits anti-tumor activity.

MDL 201112 is a carbocyclic nucleoside. MDL 201112 can decrease TNF-α production and inhibit MHC class II Ia+ antigen expression. MDL 201112 can be used for the research of inflammation and immunology.

dA-NHbenzylSCF 3 is a radiosensitizer. dA-NHbenzylSCF 3 has low toxicity to cancer cells and normal cells, but can significantly enhance cancer cell death in the presence of ionizing radiation (IR). dA-NHbenzylSCF 3 promotes cell apoptosis by capturing electrons and inducing DNA double strand breaks (DSBs). dA-NHbenzylSCF 3 is often used in the research of cancer, such as prostate cancer and breast cancer.

CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27  nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia.

CX116 is an orally active anti-inflammatory agent. CX116 exerts its effects by inhibiting the inflammatory response, reducing oxidative stress, protecting mitochondrial function, and counteracting apoptosis. CX116 bears acceptable toxicity, and can significantly protect renal tissue from Cisplatin-induced damage. CX116 can be used for the study of Cisplatin-induced acute kidney injury (cis-AKI).

AL 0671 is a potassium channel opener. AL 0671 can inhibit nonenzymatic glycation of protein and LDL oxidation. AL 0671 can be used for the researches of cardiovascular and metabolic disease, such as hypertensive diabetes.